PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Hangzhou Biotest Biotech Co., Ltd.

USPTO PatentsView assignee record - 30 granted patents across 3 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE).

Explore the portfolio See the ranking
30
Total patents granted
3
CPC technology areas
5.6
Avg claims per patent
-
5-year grant velocity

The verdict

According to USPTO PatentsView, Hangzhou ranks #10,340 of 50,000 tracked US assignees by granted-patent volume, with 30 patents across 3 technology areas.

#10,340
of 50,000 US assignees by volume
Top 60%
by Innovation Score (32.2/100)
5.6
avg claims per patent

Portfolio overview

Hangzhou Biotest Biotech Co., Ltd. has been granted 30 US utility patents between 2020 and 2025, placing Hangzhou Biotest Biotech Co., Ltd. at #10,340 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 5.6 claims per patent with primary concentration in B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE). As a Foreign Corporation, Hangzhou Biotest Biotech Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Hangzhou sits between Gibbs Technologies Limited (30 patents, rank #10,336) and Hongik University Industry-academia Cooperation Foundation (30 patents, rank #10,344) - the closest US assignees by grant volume. The composite Innovation Score of 32.2/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Historical data spans 2020 through 2025, with 30 total grants over that period. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Hangzhou Biotest Biotech Co., Ltd.'s 5.6 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 3 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Hangzhou's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Hangzhou holds 30 patents at rank #10,340, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Hangzhou

By rank, the assignees closest to #10,340 in granted patent volume.

Leaders in B01L (Chemical OR Physical Laboratory Apparatus FOR General USE)

Other assignees with the most granted patents in Hangzhou's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Hangzhou, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (32 here).

Flowcardia, Inc. 32 Winklevoss IP, Llc 32 Probiotical S.p.a. 32 Redpine Signals, Inc. 32

Hangzhou's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 Top 60% higher than 40% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

246810 202020212022202320242025 9
USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Hangzhou Biotest Biotech Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 5 16.7%
2021 3 10.0%
2022 6 20.0%
2023 4 13.3%
2024 3 10.0%
2025partial year 9 30.0%

Which technologies does Hangzhou Biotest Biotech Co., Ltd. patent most?

Top 3 of 3 technology areas

Grant record at a glance

Portfolio Volume 30 grants
CPC subclasses 3
Avg. claims / grant 5.6

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#10,340

of 50,000 tracked assignees

Innovation Score

32.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Hangzhou Biotest Biotech Co., Ltd. rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Hangzhou Biotest Biotech Co., Ltd. ranks #10,340 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Hangzhou Biotest Biotech Co., Ltd. hold?
Hangzhou Biotest Biotech Co., Ltd. holds 30 US utility patents granted between 2020 and 2025, spanning 3 technology areas.
What is Hangzhou Biotest Biotech Co., Ltd.'s Innovation Score?
Hangzhou Biotest Biotech Co., Ltd. has an Innovation Score of 32.2 out of 100 (top 60% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Hangzhou Biotest Biotech Co., Ltd. focus on?
Hangzhou Biotest Biotech Co., Ltd.'s top technology area is B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE) with 8 patents. Grants appear in 3 CPC subclasses total.
Is Hangzhou Biotest Biotech Co., Ltd.'s patent grant rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Hangzhou Biotest Biotech Co., Ltd..
What does claim depth mean for Hangzhou Biotest Biotech Co., Ltd.'s patents?
Hangzhou Biotest Biotech Co., Ltd.'s patents average 5.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Hangzhou Biotest Biotech Co., Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Hangzhou's 30 grants land it in the top 60% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Hangzhou ranks #10,340 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in B01L - see who else leads that technology area. B01L leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.